JUNEL 1/20
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUNEL 1/20 (JUNEL 1/20).
Combination estrogen-progestin contraceptive. Ethinyl estradiol is a synthetic estrogen that suppresses gonadotropin release by inhibiting hypothalamic GnRH secretion. Norethindrone acetate is a progestin that suppresses LH surge and thickens cervical mucus to inhibit sperm penetration and alters endometrial development.
| Metabolism | Ethinyl estradiol is primarily metabolized by CYP3A4, with additional contributions from CYP2C9 and CYP2C19. Norethindrone acetate is metabolized via reduction and conjugation (glucuronidation and sulfation). Both undergo first-pass metabolism in the liver and intestinal wall. |
| Excretion | Renal: 30-50% (metabolites as glucuronide and sulfate conjugates). Fecal: 20-40% (biliary elimination of metabolites). Unchanged drug: <5% renal. |
| Half-life | Ethinyl estradiol: 12-24 hours (terminal half-life). Norethindrone: 5-14 hours (terminal half-life). Achieves steady state within 5-7 days. |
| Protein binding | Ethinyl estradiol: 97-98% bound to albumin and SHBG. Norethindrone: 90% bound to albumin and SHBG. |
| Volume of Distribution | Ethinyl estradiol: 2.5-4.0 L/kg. Norethindrone: 2.5-4.0 L/kg. Large Vd indicates extensive tissue distribution. |
| Bioavailability | Oral: Ethinyl estradiol 38-48% (first-pass metabolism). Norethindrone 50-65% (first-pass metabolism). |
| Onset of Action | Oral: Contraceptive effect requires 7 days of continuous dosing; for immediate effect, start on day 1 of menstrual period. |
| Duration of Action | 24 hours (daily dosing required). Clinical note: Missed pills reduce contraceptive efficacy; back-up method needed if >2 pills missed. |
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days, then repeat.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based dose adjustment; contraindicated in patients with renal impairment if associated with hyperkalemia or other contraindications. |
| Liver impairment | Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For mild impairment (Child-Pugh A), use with caution; no specific dose adjustment established. |
| Pediatric use | Post-menarche adolescents: same dosing as adults (1 tablet daily for 21 days, then 7 placebo days). Weight-based dosing not applicable. |
| Geriatric use | Not indicated for postmenopausal women; use only in reproductive-age individuals. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JUNEL 1/20 (JUNEL 1/20).
| Breastfeeding | Small amounts of ethinyl estradiol and norethindrone are excreted in human milk. No significant adverse effects reported in nursing infants. M/P ratio not established. May reduce milk production. Use with caution in breastfeeding women, especially during early postpartum period. |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: Use associated with congenital anomalies, including cardiovascular defects and neural tube defects. Second and third trimesters: May cause fetal harm, including feminization of male fetuses and other adverse outcomes. Discontinue immediately if pregnancy occurs. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Known or suspected estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior OC use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component of the product","Smoking in women over 35 years of age"]
| Precautions | ["Increased risk of thromboembolic events (e.g., stroke, MI, DVT, PE)","Hepatic neoplasia (benign and malignant)","Gallbladder disease","Hypertension","Carbohydrate and lipid effects","Ocular changes (e.g., retinal thrombosis)","Headache/migraine","Bleeding irregularities","Depression","Carcinoma risks (breast, cervical)","Hereditary angioedema","Chloasma","Reduced efficacy with concomitant CYP3A4 inducers","Pregnancy (should be ruled out before use)"] |
Loading safety data…
| Fetal Monitoring | Monitor blood pressure, blood glucose, liver function, and lipid profile regularly. Assess for thromboembolic events. Perform pregnancy test prior to initiation and if pregnancy suspected. Fetal monitoring not indicated as drug is contraindicated in pregnancy. |
| Fertility Effects | Suppresses ovulation. May cause delayed return to fertility after discontinuation; return to baseline ovulation typically occurs within 1-3 months. No permanent effect on fertility. |